RE:RE:RE:RE:RE:RE:RE:ManipulationFGPStock ... Breakthrough designation application (or ability to apply for (or submit)) has always been targeted late 2022, as per TLT's own corporate presentation, as it represents the 450-day milestone of patient #25. No confusion there for me (only your interpretation of what you could have read). Then the FDA has to response with 60-days of reception. The only event we have no way of knowing is when such application will be submitted. And no way to know when all documents (exams, etc ...) will have been forwarded by urologists to Theralase. Don't know what's complicated in all this. It's a simple process, with some unknowns and some clear triggers.
You interpreted "Breakthrough designation" late 2022 as response from the FDA. Your problem. Not mine. Everything has always been clear on my side.
Concerning commercial revenues (projected) ealry 2023, it can only logically come from AA. Not because of Brekathrough, as per all the FDA documentation that exists. Unless there's another events that we're not aware of, as of today.
So pp was required given the low kitty and the unknown of when would the FDA response would come. I don't know why TLT would have done a pp if it was not required, as per your own statement.